ClinicalTrials.Veeva

Menu

Metformin Treatment in Polycystic Ovary Syndrome (PCOS)

Mass General Brigham logo

Mass General Brigham

Status

Unknown

Conditions

Polycystic Ovary Syndrome

Treatments

Drug: Metformin ER

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT02198417
R01HD065029 (U.S. NIH Grant/Contract)
2014P000911

Details and patient eligibility

About

PCOS occurs when a woman does not release an egg regularly each month, causing her periods to be irregular. Women with PCOS can also have increased hair growth on the face and body, acne, head balding, infertility, pre-diabetes, and diabetes. PCOS is commonly treated with oral contraceptive pills (also known as the birth control pills). Sometimes, a medication called metformin is also used to treat PCOS, especially if a woman has evidence of insulin resistance or if fertility is desired. Unfortunately, metformin works in only some women with PCOS. The mechanism through which metformin works in PCOS is not clear and it difficult to predict who will benefit from metformin treatment and who will not.

The investigators are doing this research study to look at how the medication metformin affects the cells in the body of patients with PCOS. Specifically, the investigators will look at how metformin affects the mitochondria. Mitochondria are the part of cells that produce fuel (energy) for other cells and play a role in metabolism. The investigators would like to see whether there is a relationship between mitochondrial activity and symptoms of polycystic ovary syndrome (PCOS) before and after treatment with metformin. They would also like to study whether genes affect the response to metformin in women with PCOS.

Full description

Women who are eligible to enroll in this study will be treated with the medication metformin for 12 weeks. Before and after treatment with metformin, the following will be assessed:

  • Weight, blood pressure, waist circumference
  • Lipids (cholesterol)
  • Hormone levels (including testosterone and other androgens)
  • IV glucose tolerance test (to assess for early evidence of insulin resistance)
  • Effect of metformin on muscle mitochondria (this will involve one MRI scan and one muscle biopsy each before and after treatment with metformin)

Ovulation will be closely monitored at least twice a month with pelvic ultrasounds and blood tests for estrogen and progesterone levels.

Enrollment

20 estimated patients

Sex

Female

Ages

18 to 40 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Polycystic ovary syndrome
  • No hormonal or antidiabetic medications for 1 month
  • Good general health

Exclusion criteria

  • Smoker
  • Acute infection or chronic disease
  • Diabetes
  • Pregnant or trying to get pregnant over next half year
  • Bleeding disorders
  • Any metal or foreign implants (e.g., aneurysm clips, ear implants, heart pacemakers or defibrillators)

Trial design

Primary purpose

Basic Science

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

20 participants in 1 patient group

Metformin
Experimental group
Description:
Metformin ER 1500 mg per day treatment for 12 weeks
Treatment:
Drug: Metformin ER

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems